1-butanol has been researched along with Hypomelanosis in 28 studies
1-Butanol: A four carbon linear hydrocarbon that has a hydroxy group at position 1.
butan-1-ol : A primary alcohol that is butane in which a hydrogen of one of the methyl groups is substituted by a hydroxy group. It it produced in small amounts in humans by the gut microbes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A small proportion of individuals utilizing cosmetics containing rhododendrol developed leukoderma with various pathological conditions, in some cases indistinguishable from vitiligo." | 9.12 | Rhododendrol-induced leukoderma update II: Pathophysiology, mechanisms, risk evaluation, and possible mechanism-based treatments in comparison with vitiligo. ( Abe, Y; Inoue, S; Ito, A; Ito, S; Katayama, I; Masui, Y; Matsunaga, K; Sumikawa, Y; Suzuki, K; Suzuki, T; Tanemura, A; Yagami, A; Yoshikawa, M, 2021) |
| " Immunization of mice with rhododendrol-treated and irradiated B16 melanoma cells successfully delayed the growth of melanoma cells in vivo." | 7.83 | T-Cell Responses to Tyrosinase-Derived Self-Peptides in Patients with Leukoderma Induced by Rhododendrol: Implications for Immunotherapy Targeting Melanoma. ( Kawano, M; Matsushita, S; Nakamura, K; Takagi, R; Tsuchida, T, 2016) |
| "A small proportion of individuals utilizing cosmetics containing rhododendrol developed leukoderma with various pathological conditions, in some cases indistinguishable from vitiligo." | 5.12 | Rhododendrol-induced leukoderma update II: Pathophysiology, mechanisms, risk evaluation, and possible mechanism-based treatments in comparison with vitiligo. ( Abe, Y; Inoue, S; Ito, A; Ito, S; Katayama, I; Masui, Y; Matsunaga, K; Sumikawa, Y; Suzuki, K; Suzuki, T; Tanemura, A; Yagami, A; Yoshikawa, M, 2021) |
| " Immunization of mice with rhododendrol-treated and irradiated B16 melanoma cells successfully delayed the growth of melanoma cells in vivo." | 3.83 | T-Cell Responses to Tyrosinase-Derived Self-Peptides in Patients with Leukoderma Induced by Rhododendrol: Implications for Immunotherapy Targeting Melanoma. ( Kawano, M; Matsushita, S; Nakamura, K; Takagi, R; Tsuchida, T, 2016) |
| "Bimatoprost is a prostaglandin F2α analog and is often used for eyelash growth for cosmetic reasons as well as in the treatment of glaucoma." | 2.87 | Open-label pilot study to evaluate the effectiveness of topical bimatoprost on rhododendrol-induced refractory leukoderma. ( Fukaya, S; Fukuyasu, A; Hayashi, K; Iimuro, S; Ishikawa, T; Kamata, M; Kasanuki, T; Ohnishi, T; Tada, Y; Takeoka, S; Tanaka, T; Watanabe, S; Yokobori, M, 2018) |
| "Rhododendrol (RD) was approved as a cosmetic ingredient in Japan in 2008." | 1.62 | Zebrafish as a new model for rhododendrol-induced leukoderma. ( Akiyama, T; Hamamoto, A; Hatano, O; Hayazaki, M; Shimabayashi, S; Takemori, H, 2021) |
| " Our results help to elucidate the development mechanisms of RD-induced leukoderma and provide information for innovation of safe skin-whitening compounds." | 1.48 | 4-(4-Hydroxyphenyl)-2-butanol (rhododendrol)-induced melanocyte cytotoxicity is enhanced by UVB exposure through generation of oxidative stress. ( Goto, N; Ito, S; Masaki, T; Nagai, H; Nishigori, C; Tsujimoto, M; Wakamatsu, K, 2018) |
| "Hydroxyl radicals were generated depending on the amounts of rhododendrol and/or tyrosinase." | 1.48 | Substantial evidence for the rhododendrol-induced generation of hydroxyl radicals that causes melanocyte cytotoxicity and induces chemical leukoderma. ( Baba, T; Gabe, Y; Hachiya, A; Kohno, M; Miyaji, A; Moriwaki, S, 2018) |
| "Rhododendrol is a phenolic compound that shows a tyrosinase-dependent toxicity for melanocytes and occasionally induces a vitiligo-like skin depigmentation." | 1.43 | Glutathione maintenance is crucial for survival of melanocytes after exposure to rhododendrol. ( Hachiya, A; Inoue, S; Kawabata, K; Kondo, M; Sato, K; Takahashi, Y; Yamaguchi, S, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 21 (75.00) | 24.3611 |
| 2020's | 7 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bjerke, DL | 1 |
| Wu, S | 1 |
| Wakamatsu, K | 3 |
| Ito, S | 6 |
| Wang, J | 1 |
| Laughlin, T | 1 |
| Hakozaki, T | 1 |
| Abe, Y | 5 |
| Okamura, K | 2 |
| Hozumi, Y | 2 |
| Suzuki, T | 10 |
| Katahira, Y | 1 |
| Sakamoto, E | 1 |
| Watanabe, A | 1 |
| Furusaka, Y | 1 |
| Inoue, S | 5 |
| Hasegawa, H | 1 |
| Mizoguchi, I | 1 |
| Yo, K | 1 |
| Yamaji, F | 1 |
| Toyoda, A | 1 |
| Yoshimoto, T | 1 |
| Arase, N | 2 |
| Tanemura, A | 7 |
| Jin, H | 1 |
| Nishioka, M | 2 |
| Aoyama, Y | 2 |
| Oiso, N | 2 |
| Matsunaga, K | 9 |
| Nishigori, C | 3 |
| Kawamura, T | 1 |
| Shimizu, T | 1 |
| Ito, A | 4 |
| Fukai, K | 3 |
| Yang, L | 4 |
| Tsuruta, D | 3 |
| Takeoka, K | 1 |
| Iwatani, Y | 1 |
| Hidaka, Y | 1 |
| Nishida, M | 1 |
| Yamauchi-Takihara, K | 1 |
| Arase, H | 1 |
| Fujimoto, M | 1 |
| Katayama, I | 7 |
| Fukaya, S | 2 |
| Kamata, M | 2 |
| Kasanuki, T | 2 |
| Yokobori, M | 2 |
| Takeoka, S | 2 |
| Hayashi, K | 2 |
| Tanaka, T | 3 |
| Fukuyasu, A | 2 |
| Ishikawa, T | 2 |
| Ohnishi, T | 2 |
| Iimuro, S | 2 |
| Watanabe, S | 3 |
| Tada, Y | 2 |
| Sasaki, M | 2 |
| Okajima, T | 1 |
| Miyaki, M | 1 |
| Sakaguchi, H | 1 |
| Suzuki, K | 4 |
| Yoshikawa, M | 2 |
| Sumikawa, Y | 2 |
| Yagami, A | 4 |
| Masui, Y | 2 |
| Hayazaki, M | 1 |
| Hatano, O | 1 |
| Shimabayashi, S | 1 |
| Akiyama, T | 1 |
| Takemori, H | 1 |
| Hamamoto, A | 1 |
| Iwata, Y | 2 |
| Nagai, A | 1 |
| Kuroda, M | 1 |
| Sugiura, K | 1 |
| Goto, N | 1 |
| Tsujimoto, M | 1 |
| Nagai, H | 1 |
| Masaki, T | 1 |
| Gabe, Y | 1 |
| Miyaji, A | 1 |
| Kohno, M | 1 |
| Hachiya, A | 3 |
| Moriwaki, S | 2 |
| Baba, T | 1 |
| Iida, M | 1 |
| Tazaki, A | 1 |
| Deng, Y | 1 |
| Chen, W | 1 |
| Yajima, I | 1 |
| Kondo-Ida, L | 1 |
| Hashimoto, K | 1 |
| Ohgami, N | 1 |
| Kato, M | 1 |
| Kondo, M | 2 |
| Sato, K | 2 |
| Umeda, M | 1 |
| Kawabata, K | 2 |
| Takahashi, Y | 2 |
| Kasamatsu, S | 1 |
| Nakamura, S | 1 |
| Yasuda, Y | 1 |
| Fujimori, T | 1 |
| Takano, K | 1 |
| Hase, T | 1 |
| Ito, M | 1 |
| Kagohashi, Y | 1 |
| Sugiura, S | 1 |
| Funasaka, Y | 1 |
| Yamashita, T | 1 |
| Yang, F | 2 |
| Nagata, Y | 1 |
| Wataya-Kaneda, M | 2 |
| Ohe, R | 1 |
| Yamakawa, M | 1 |
| Fujiyama, T | 2 |
| Ikeya, S | 2 |
| Ito, T | 2 |
| Tatsuno, K | 2 |
| Aoshima, M | 2 |
| Kasuya, A | 2 |
| Sakabe, J | 1 |
| Tokura, Y | 2 |
| Tanaka, A | 1 |
| Sano, A | 1 |
| Takahashi, M | 1 |
| Kobayashi, T | 1 |
| Morita, Y | 1 |
| Ando, A | 1 |
| Takagi, R | 1 |
| Kawano, M | 1 |
| Nakamura, K | 1 |
| Tsuchida, T | 1 |
| Matsushita, S | 1 |
| Inoue, M | 1 |
| Kikuchi, K | 1 |
| Watabe, A | 1 |
| Yamasaki, K | 1 |
| Aiba, S | 1 |
| Yamaguchi, S | 1 |
| Hayashi, M | 1 |
| Araki, Y | 1 |
| Suzuki, M | 1 |
| Nakano, S | 1 |
| Yoshizawa, J | 1 |
| Inoie, M | 1 |
4 reviews available for 1-butanol and Hypomelanosis
| Article | Year |
|---|---|
Rhododendrol-induced leukoderma update I: Clinical findings and treatment.
Topics: Butanols; Humans; Hypopigmentation; Melanocytes; Quality of Life | 2021 |
Rhododendrol-induced leukoderma update II: Pathophysiology, mechanisms, risk evaluation, and possible mechanism-based treatments in comparison with vitiligo.
Topics: Butanols; Humans; Hypopigmentation; Melanocytes; Vitiligo | 2021 |
Biochemical Mechanism of Rhododendrol-Induced Leukoderma.
Topics: Animals; Butanols; Humans; Hypopigmentation; Melanocytes; Monophenol Monooxygenase; Reactive Oxygen | 2018 |
Biochemical, cytological, and immunological mechanisms of rhododendrol-induced leukoderma.
Topics: Butanols; CD8-Positive T-Lymphocytes; Cosmetics; Humans; Hypopigmentation; Melanocytes; Monophenol M | 2015 |
1 trial available for 1-butanol and Hypomelanosis
| Article | Year |
|---|---|
Open-label pilot study to evaluate the effectiveness of topical bimatoprost on rhododendrol-induced refractory leukoderma.
Topics: Administration, Cutaneous; Adult; Aged; Bimatoprost; Butanols; Drug Resistance; Female; Humans; Hypo | 2018 |
23 other studies available for 1-butanol and Hypomelanosis
| Article | Year |
|---|---|
A framework to mitigate the risk of chemical leukoderma: Consumer products.
Topics: Butanols; Epidermis; Humans; Hypopigmentation; Melanocytes; Resveratrol; Skin | 2022 |
The effect of a topical vitamin D3 analog on repigmentation in mice with rhododendrol-induced leukoderma.
Topics: Animals; Butanols; Cholecalciferol; Hypopigmentation; Mice | 2022 |
Upregulation of CD86 and IL-12 by rhododendrol in THP-1 cells cocultured with melanocytes through ROS and ATP.
Topics: Adenosine Triphosphate; B7-2 Antigen; Butanols; Coculture Techniques; Humans; Hypopigmentation; Inte | 2022 |
Autoantibodies detected in patients with vitiligo vulgaris but not in those with rhododendrol-induced leukoderma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Autoantibodies; Butanols; Child, Preschool; Female; Huma | 2019 |
Long-term Use of Topical Bimatoprost on Rhododendrol-induced Refractory Leukoderma: A Case Report.
Topics: Administration, Cutaneous; Adult; Bimatoprost; Butanols; Cosmetics; Dermatologic Agents; Drug Admini | 2019 |
Improvement in the quality of life of patients with rhododendrol-induced leukoderma after camouflaging with dihydroxyacetone cream.
Topics: Butanols; Dihydroxyacetone; Humans; Hypopigmentation; Quality of Life | 2020 |
Zebrafish as a new model for rhododendrol-induced leukoderma.
Topics: Animals; Butanols; Disease Models, Animal; Hypopigmentation; Zebrafish | 2021 |
Retention of pigment stem cells in Rhododenol-induced leukoderma: Pathological investigation of 11 patients.
Topics: Adult; Aged; Butanols; Cosmetics; Drug Eruptions; Female; Humans; Hypopigmentation; Japan; Middle Ag | 2017 |
4-(4-Hydroxyphenyl)-2-butanol (rhododendrol)-induced melanocyte cytotoxicity is enhanced by UVB exposure through generation of oxidative stress.
Topics: Acetylcysteine; Antioxidants; Apoptosis; Butanols; Caspase Inhibitors; Cell Survival; Cells, Culture | 2018 |
Substantial evidence for the rhododendrol-induced generation of hydroxyl radicals that causes melanocyte cytotoxicity and induces chemical leukoderma.
Topics: Antioxidants; Butanols; Cell Line; Cell Survival; Humans; Hydroxyl Radical; Hypopigmentation; Melano | 2018 |
A unique system that can sensitively assess the risk of chemical leukoderma by using murine tail skin.
Topics: Animals; Butanols; Butanones; Epidermal Cells; Epidermis; Humans; Hypersensitivity; Hypopigmentation | 2019 |
Rhododendrol, a depigmentation-inducing phenolic compound, exerts melanocyte cytotoxicity via a tyrosinase-dependent mechanism.
Topics: Agaricales; Apoptosis; Butanols; Caspase 3; Catalytic Domain; Cell Survival; Cells, Cultured; Chelat | 2014 |
Depigmentation caused by application of the active brightening material, rhododendrol, is related to tyrosinase activity at a certain threshold.
Topics: Bleaching Agents; Butanols; Cell Survival; Humans; Hypopigmentation; Melanins; Melanocytes; Monophen | 2014 |
Guide for medical professionals (i.e., dermatologists) for the management of Rhododenol-induced leukoderma.
Topics: Butanols; Cosmetics; Drug Eruptions; Humans; Hypopigmentation; Skin Lightening Preparations | 2015 |
An immune pathological and ultrastructural skin analysis for rhododenol-induced leukoderma patients.
Topics: Butanols; CD4-CD8 Ratio; Cosmetics; Fibroblasts; Humans; Hypopigmentation; MART-1 Antigen; Melanocyt | 2015 |
4-(4-hydroroxyphenyl)-2-butanol (rhododendrol) activates the autophagy-lysosome pathway in melanocytes: insights into the mechanisms of rhododendrol-induced leukoderma.
Topics: Autophagy; Butanols; Cell Survival; Cells, Cultured; Humans; Hypopigmentation; Lysosomes; Melanins; | 2015 |
Melanocyte-specific cytotoxic T lymphocytes in patients with rhododendrol-induced leukoderma.
Topics: Butanols; Cosmetics; Genotype; HLA-A24 Antigen; Humans; Hypopigmentation; MART-1 Antigen; Melanocyte | 2015 |
Possible involvement of CCR4+ CD8+ T cells and elevated plasma CCL22 and CCL17 in patients with rhododenol-induced leukoderma.
Topics: Butanols; CD8-Positive T-Lymphocytes; Chemokine CCL17; Chemokine CCL22; Cosmetics; Humans; Hypopigme | 2015 |
Rhododendrol-induced leukoderma accompanied by allergic contact dermatitis caused by a non-rhododendrol skin-lightening agent, 5,5'-dipropylbiphenyl-2,2'-diol.
Topics: Biphenyl Compounds; Butanols; Dermatitis, Allergic Contact; Female; Humans; Hypopigmentation; Middle | 2015 |
T-Cell Responses to Tyrosinase-Derived Self-Peptides in Patients with Leukoderma Induced by Rhododendrol: Implications for Immunotherapy Targeting Melanoma.
Topics: Animals; Butanols; Cell Culture Techniques; Disease Models, Animal; Female; Humans; Hypopigmentation | 2016 |
The spectrophotometrical analysis of rhododendrol-induced leucoderma using a novel multispectral camera.
Topics: Adult; Aged; Butanols; Case-Control Studies; Diagnosis, Differential; Female; Humans; Hypopigmentati | 2016 |
Glutathione maintenance is crucial for survival of melanocytes after exposure to rhododendrol.
Topics: Butanols; Cell Survival; Cells, Cultured; Glutathione; Humans; Hypopigmentation; Melanocytes; Protec | 2016 |
A novel three dimensional imaging method for the measurement of area in vitiligo and chemical leukoderma.
Topics: Adolescent; Adult; Aged; Butanols; Cellular Senescence; Cosmetics; Female; Humans; Hypopigmentation; | 2016 |